What is the duration of action of Vonaprazon (proton pump inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Action of Vonaprazan

Vonaprazan maintains acid suppression for over 24 hours after a single 20 mg dose, with an elimination half-life of approximately 6.8-7.7 hours. 1, 2

Pharmacodynamic Duration

  • The antisecretory effect of vonaprazan begins within 2-3 hours after a single 20 mg dose and is maintained for over 24 hours. 1

  • Following discontinuation of therapy, the intragastric pH remains elevated compared to placebo for 24 to 48 hours after the final dose on Day 7, demonstrating prolonged pharmacodynamic effects that outlast plasma drug levels. 1

  • At steady state (achieved by Day 3-4), vonaprazan maintains the 24-hour intragastric pH >4 holding time ratio at 83% on Day 7 of repeated 20 mg once-daily dosing. 2

Pharmacokinetic Half-Life

  • The mean apparent terminal elimination half-life is 6.8-7.7 hours in healthy adults at steady state. 1, 2

  • Despite this relatively short plasma half-life, vonaprazan accumulates and is retained in the stomach for more than 24 hours, even after elimination from plasma, explaining the prolonged duration of action. 3

Mechanism Explaining Prolonged Action

  • Vonaprazan is a potassium-competitive acid blocker (P-CAB) with reversible but slow dissociation from the H+,K+-ATPase receptor, which contributes to its extended duration of effect. 4, 1

  • Being a base with pKa of 9.6 and acid-resistant properties, vonaprazan concentrates highly in the acidic canaliculi of gastric parietal cells, allowing it to elicit acid suppression for longer than 24 hours after a 20 mg dose. 2

  • The drug inhibits TRAP-induced platelet aggregation for up to 4 weeks in the context of vorapaxar (a different PAR-1 antagonist), though this refers to a different drug class and should not be confused with vonaprazan's gastric acid suppression duration. 4

Clinical Implications

  • The once-daily dosing regimen (20 mg for treatment, 10 mg for maintenance) is supported by the >24-hour duration of antisecretory action. 1, 5

  • Steady-state plasma exposure is approximately 1.8-fold higher compared to Day 1, with steady state achieved by Day 3-4 of repeated dosing. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.